172 related articles for article (PubMed ID: 2308981)
1. Bone marrow purging with immunotoxins for treatment of T cell acute lymphoblastic leukemia (T-ALL).
Vallera DA; Uckun FM
Prog Clin Biol Res; 1990; 333():191-204; discussion 205. PubMed ID: 2308981
[No Abstract] [Full Text] [Related]
2. Depletion of bone marrow T-lymphocytes with an anti-CD5 monoclonal immunotoxin (ST-1 immunotoxin): effective prophylaxis for graft-versus-host disease.
Antin JH; Bierer BE; Smith BR; Guinan EC; Provost MM; Ferrara J; Macklis RM; Tarbell NJ; Blythman H; Bouloux C
Prog Clin Biol Res; 1990; 333():207-15. PubMed ID: 1689852
[No Abstract] [Full Text] [Related]
3. Efficacy of an anti-CD7-ricin A chain immunoconjugate in a novel murine model of human T-cell leukemia.
Fishwild DM; Aberle S; Bernhard SL; Kung AH
Cancer Res; 1992 Jun; 52(11):3056-62. PubMed ID: 1375534
[TBL] [Abstract][Full Text] [Related]
4. Combined ex vivo treatment with immunotoxins and mafosfamid: a novel immunochemotherapeutic approach for elimination of neoplastic T cells from autologous marrow grafts.
Uckun FM; Stong RC; Youle RJ; Vallera DA
J Immunol; 1985 May; 134(5):3504-15. PubMed ID: 3884712
[TBL] [Abstract][Full Text] [Related]
5. Autologous bone marrow transplantation for acute lymphoblastic leukemia: role of bone marrow purging.
Canals C; Picón M; Sanchez T; Torrico C; Amill B; Tugues D; Sierra J; Grañena A; Badell I; Brunet S
Prog Clin Biol Res; 1994; 389():125-32. PubMed ID: 7700894
[No Abstract] [Full Text] [Related]
6. T-cell depletion with ricin A-chain T101 in allogeneic bone marrow transplantation to prevent severe graft-versus-host disease.
Fauser AA; Shustik C; Langleben A; Laurent G; Kanz L; Spurll GM; Price G; Ahlgren PD; Cooper BA
Clin Invest Med; 1988 Feb; 11(1):40-6. PubMed ID: 3284672
[TBL] [Abstract][Full Text] [Related]
7. In vitro treatment of bone marrow from patients with T-cell acute lymphoblastic leukemia and non-Hodgkin's lymphoma using the immunotoxin WT1-ricin A.
Barnett MJ; Rohatiner AZ; Kingston JE; Adams KE; Batten EL; Bassan R; Thorpe PE; Horton MA; Malpas JS; Lister TA
Haematol Blood Transfus; 1987; 31():57-8. PubMed ID: 3327786
[No Abstract] [Full Text] [Related]
8. [Ex vivo purging methods for autologous bone marrow transplantation].
Kojima S; Ueda R
Nihon Rinsho; 1990 Sep; 48(9):2117-24. PubMed ID: 2232217
[No Abstract] [Full Text] [Related]
9. Autologous bone marrow transplantation with marrow decontaminated by immunotoxin T 101 in the treatment of leukemia and lymphoma: first clinical observations.
Gorin NC; Douay L; Laporte JP; Lopez M; Zittoun R; Rio B; David R; Stachowiak J; Jansen J; Cazellas P
Cancer Treat Rep; 1985 Sep; 69(9):953-9. PubMed ID: 3896482
[TBL] [Abstract][Full Text] [Related]
10. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors.
Koehler M; Hurwitz CA; Krance RA; Coustan-Smith E; Williams LL; Santana V; Ribeiro RC; Brenner MK; Heslop HE
Bone Marrow Transplant; 1994 May; 13(5):571-5. PubMed ID: 7519937
[TBL] [Abstract][Full Text] [Related]
11. Ex vivo depletion of human bone marrow T lymphocytes by soybean lectin fractionation followed by treatment with an anti-pan-T cell (CD5) ricin A- chain immunotoxin.
Siena S; Villa S; Bonadonna G; Bregni M; Gianni AM
Transplant Proc; 1987 Feb; 19(1 Pt 3):2735-7. PubMed ID: 3274583
[No Abstract] [Full Text] [Related]
12. Immunopharmacologic purging of breast cancer from bone marrow for autologous bone marrow transplantation.
Shpall EJ; Anderson IC; Bast RC; Joines WT; Jones RB; Ross M; Edwards S; Eggleston S; Johnston C; Tepperberg M
Prog Clin Biol Res; 1990; 333():321-35; discussion 336. PubMed ID: 2308989
[No Abstract] [Full Text] [Related]
13. Autologous transplantation of bone marrow purged in vitro with anti-CD7-(WT1-) ricin A immunotoxin in T-cell lymphoblastic leukemia and lymphoma.
Preijers FW; De Witte T; Wessels JM; De Gast GC; Van Leeuwen E; Capel PJ; Haanen C
Blood; 1989 Aug; 74(3):1152-8. PubMed ID: 2473811
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxicity of CD3-ricin A chain immunotoxins in relation to cellular uptake and degradation kinetics.
van Oosterhout YV; Preijers FW; Wessels HM; de Witte T
Cancer Res; 1992 Nov; 52(21):5921-5. PubMed ID: 1394218
[TBL] [Abstract][Full Text] [Related]
15. Prevention of graft-versus-host disease with anti-CD5 ricin A chain immunotoxin after CD3-depleted HLA-nonidentical marrow transplantation in pediatric leukemia patients.
Przepiorka D; Chan KW; Champlin RE; Culbert SJ; Petropoulos D; Ippoliti C; Khouri I; Huh YO; Vreisendorp H; Deisseroth AB
Bone Marrow Transplant; 1995 Dec; 16(6):737-41. PubMed ID: 8750262
[TBL] [Abstract][Full Text] [Related]
16. Immunomagnetic bone marrow purging of common acute lymphoblastic leukemia cells: suitability of BioMag particles.
Trickett AE; Ford DJ; Lam-Po-Tang PR; Vowels MR
Bone Marrow Transplant; 1991 Mar; 7(3):199-203. PubMed ID: 2059757
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of bone marrow purging in AML using monoclonal antibodies and complement.
Mills LE; Ball ED; Howell AL; Cornwell GG; Thompson L; Spruce W; Miller WE; McMillan R
Prog Clin Biol Res; 1990; 333():165-70. PubMed ID: 2308980
[No Abstract] [Full Text] [Related]
18. Combination graft-versus-host disease prophylaxis using immunotoxin (anti-CD5-RTA [Xomazyme-CD5]) plus methotrexate and cyclosporine or prednisone after unrelated donor marrow transplantation.
Weisdorf D; Filipovich A; McGlave P; Ramsay N; Kersey J; Miller W; Blazar B
Bone Marrow Transplant; 1993 Nov; 12(5):531-6. PubMed ID: 8298565
[TBL] [Abstract][Full Text] [Related]
19. Efficient transplantation of human non-T-leukemia cells into nude mice and induction of complete regression of the transplanted distinct tumors by ricin A-chain conjugates of monoclonal antibodies SN5 and SN6.
Hara H; Luo Y; Haruta Y; Seon BK
Cancer Res; 1988 Aug; 48(16):4673-80. PubMed ID: 2969282
[TBL] [Abstract][Full Text] [Related]
20. A new approach to the prevention of graft-versus-host disease using XomaZyme-H65 following histo-incompatible partially T-depleted marrow grafts.
Henslee PJ; Byers VS; Jennings CD; Marciniak E; Thompson JS; Macdonald JS; Romond EH; Messino MJ; Scannon PJ
Transplant Proc; 1989 Feb; 21(1 Pt 3):3004-7. PubMed ID: 2650413
[No Abstract] [Full Text] [Related]
[Next] [New Search]
